<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Sight Sciences Inc — News on 6ix</title>
<link>https://6ix.com/company/sight-sciences-inc</link>
<description>Latest news and press releases for Sight Sciences Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/sight-sciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835bf5778dffbe2df118068.webp</url>
<title>Sight Sciences Inc</title>
<link>https://6ix.com/company/sight-sciences-inc</link>
</image>
<item>
<title>Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026</title>
<link>https://6ix.com/company/sight-sciences-inc/news/sight-sciences-to-report-first-quarter-2026-financial-results-on-may-6-2026</link>
<guid isPermaLink="true">https://6ix.com/company/sight-sciences-inc/news/sight-sciences-to-report-first-quarter-2026-financial-results-on-may-6-2026</guid>
<pubDate>Tue, 21 Apr 2026 20:05:00 GMT</pubDate>
<description>MENLO PARK, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the first quarter ended March 31, 2026, after the market close on Wednesday, May 6, 2026. The Company’s management will discuss the results during a confer</description>
</item>
<item>
<title>Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th</title>
<link>https://6ix.com/company/sight-sciences-inc/news/sight-sciences-to-present-at-the-25th-annual-needham-healthcare-conference-on-april-13th</link>
<guid isPermaLink="true">https://6ix.com/company/sight-sciences-inc/news/sight-sciences-to-present-at-the-25th-annual-needham-healthcare-conference-on-april-13th</guid>
<pubDate>Mon, 30 Mar 2026 20:05:00 GMT</pubDate>
<description>MENLO PARK, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at the 25th Annual Needham Healthcare Conference being held virtually. Sight Sciences’ management is scheduled to present on Monday, April 13, 2026, at 11:15 am PT / 2:15</description>
</item>
<item>
<title>Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent</title>
<link>https://6ix.com/company/sight-sciences-inc/news/sight-sciences-secures-order-on-post-trial-motions-that-preserves-the-jurys-verdict-and-awards-monetary-damages-to-sight-sciences-against-alcon-and-its-hydrusr-microstent</link>
<guid isPermaLink="true">https://6ix.com/company/sight-sciences-inc/news/sight-sciences-secures-order-on-post-trial-motions-that-preserves-the-jurys-verdict-and-awards-monetary-damages-to-sight-sciences-against-alcon-and-its-hydrusr-microstent</guid>
<pubDate>Mon, 30 Mar 2026 11:05:00 GMT</pubDate>
<description>Court preserves jury’s finding of willful infringement by Alcon, and awards past damages to Sight Sciences in excess of $34 million and ongoing royalties through November 2028MENLO PARK, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that the U.S. Dis</description>
</item>
<item>
<title>Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance</title>
<link>https://6ix.com/company/sight-sciences-inc/news/sight-sciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-initiates-full-year-2026-financial-guidance-120</link>
<guid isPermaLink="true">https://6ix.com/company/sight-sciences-inc/news/sight-sciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-initiates-full-year-2026-financial-guidance-120</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company</description>
</item>
<item>
<title>Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026</title>
<link>https://6ix.com/company/sight-sciences-inc/news/sight-sciences-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026</link>
<guid isPermaLink="true">https://6ix.com/company/sight-sciences-inc/news/sight-sciences-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026</guid>
<pubDate>Wed, 18 Feb 2026 21:05:00 GMT</pubDate>
<description>MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025, after the market close on Wednesday, March 4, 2026. The Company’s management will discuss the resu</description>
</item>
<item>
<title>Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights</title>
<link>https://6ix.com/company/sight-sciences-inc/news/sight-sciences-announces-preliminary-unaudited-120500744</link>
<guid isPermaLink="true">https://6ix.com/company/sight-sciences-inc/news/sight-sciences-announces-preliminary-unaudited-120500744</guid>
<pubDate>Tue, 13 Jan 2026 12:05:00 GMT</pubDate>
<description>MENLO PARK, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported select preliminary, unaudited financial highlights for the fourth quarter and full year ended December 31, 2025. Select Preliminary Financial Highlights Fourth quarter 2025 total revenue is expe</description>
</item>
<item>
<title>New Peer-Reviewed Publications Highlight Effectiveness of OMNI® Surgical System with TruSync™ Technology in Reducing IOP and Medication Usage in Cataract Combination Procedures, Standalone Procedures, and in African Americans</title>
<link>https://6ix.com/company/sight-sciences-inc/news/peer-reviewed-publications-highlight-effectiveness-120000548</link>
<guid isPermaLink="true">https://6ix.com/company/sight-sciences-inc/news/peer-reviewed-publications-highlight-effectiveness-120000548</guid>
<pubDate>Tue, 11 Nov 2025 12:00:00 GMT</pubDate>
<description>Prospective study data and retrospective registry data were analyzed in the manuscripts recently published by the Journal of Cataract and Refractive Surgery, Journal of Glaucoma and Clinical OphthalmologyMENLO PARK, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, announced today</description>
</item>
<item>
<title>Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance</title>
<link>https://6ix.com/company/sight-sciences-inc/news/sight-sciences-reports-third-quarter-210500201</link>
<guid isPermaLink="true">https://6ix.com/company/sight-sciences-inc/news/sight-sciences-reports-third-quarter-210500201</guid>
<pubDate>Thu, 06 Nov 2025 21:05:00 GMT</pubDate>
<description>MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the third quarter ended September 30, 2025, and raised its revenue guidance and reduced its adjusted operating expense guidance, both for full year 2025. Recent Financial a</description>
</item>
<item>
<title>Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer</title>
<link>https://6ix.com/company/sight-sciences-inc/news/sight-sciences-appoints-ali-bauerlein-210400753</link>
<guid isPermaLink="true">https://6ix.com/company/sight-sciences-inc/news/sight-sciences-appoints-ali-bauerlein-210400753</guid>
<pubDate>Thu, 06 Nov 2025 21:04:00 GMT</pubDate>
<description>New leadership appointments strengthen Sight Sciences’ commitment to advancing our interventional dry eye initiatives and driving scalable operations and growthMENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of Alison (Ali) Bauerlein as its Chie</description>
</item>
<item>
<title>Sight Sciences to Present at Two Upcoming Investor Conferences</title>
<link>https://6ix.com/company/sight-sciences-inc/news/sight-sciences-present-two-upcoming-210500298</link>
<guid isPermaLink="true">https://6ix.com/company/sight-sciences-inc/news/sight-sciences-present-two-upcoming-210500298</guid>
<pubDate>Tue, 04 Nov 2025 21:05:00 GMT</pubDate>
<description>MENLO PARK, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at the upcoming Stifel 2025 Healthcare Conference and the Piper Sandler 37th Annual Healthcare Conference, both in New York, NY. Sight Sciences’ management is scheduled to pres</description>
</item>
<item>
<title>Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025</title>
<link>https://6ix.com/company/sight-sciences-inc/news/sight-sciences-report-third-quarter-200500067</link>
<guid isPermaLink="true">https://6ix.com/company/sight-sciences-inc/news/sight-sciences-report-third-quarter-200500067</guid>
<pubDate>Thu, 23 Oct 2025 20:05:00 GMT</pubDate>
<description>MENLO PARK, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced it will report financial results for the third quarter ended September 30, 2025, after the market close on Thursday, November 6, 2025. The Company’s management will discuss the results during a</description>
</item>
<item>
<title>Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure</title>
<link>https://6ix.com/company/sight-sciences-inc/news/sight-sciences-announces-fee-schedule-110000136</link>
<guid isPermaLink="true">https://6ix.com/company/sight-sciences-inc/news/sight-sciences-announces-fee-schedule-110000136</guid>
<pubDate>Fri, 17 Oct 2025 11:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that two Medicare Administrative Contractors (MACs), Novitas Solutions, Inc. (Novitas) and First Coast Service Options, Inc. (FCSO), each established jurisdiction-wide pricing for CPT® code 056</description>
</item>
<item>
<title>Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use</title>
<link>https://6ix.com/company/sight-sciences-inc/news/sight-sciences-announces-publication-systematic-110000122</link>
<guid isPermaLink="true">https://6ix.com/company/sight-sciences-inc/news/sight-sciences-announces-publication-systematic-110000122</guid>
<pubDate>Wed, 17 Sep 2025 11:00:00 GMT</pubDate>
<description>The study, published in The European Journal of Ophthalmology, included 29 publications and concluded that favorable long-term safety and efficacy profiles make OMNI a beneficial treatment option for patients with primary open-angle glaucomaMENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform c</description>
</item>
<item>
<title>Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare’s® Expanded Coverage of Glaucoma Surgical Treatments</title>
<link>https://6ix.com/company/sight-sciences-inc/news/sight-sciences-announces-omni-surgical-110500024</link>
<guid isPermaLink="true">https://6ix.com/company/sight-sciences-inc/news/sight-sciences-announces-omni-surgical-110500024</guid>
<pubDate>Tue, 09 Sep 2025 11:05:00 GMT</pubDate>
<description>UnitedHealthcare’s Coverage Policy includes procedures enabled with OMNI Surgical System technology, the leader in implant-free MIGS, are proven and medically necessaryMENLO PARK, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that UnitedHealthcare (U</description>
</item>
<item>
<title>Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO</title>
<link>https://6ix.com/company/sight-sciences-inc/news/sight-sciences-announces-recognition-tearcare-200500698</link>
<guid isPermaLink="true">https://6ix.com/company/sight-sciences-inc/news/sight-sciences-announces-recognition-tearcare-200500698</guid>
<pubDate>Tue, 02 Sep 2025 20:05:00 GMT</pubDate>
<description>This report provides an evidence-based review of current treatments for managing dry eye disease (DED) and highlights support for TearCare based on strong clinical dataMENLO PARK, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that its TearCare System,</description>
</item>
<item>
<title>Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference</title>
<link>https://6ix.com/company/sight-sciences-inc/news/sight-sciences-present-upcoming-morgan-200500127</link>
<guid isPermaLink="true">https://6ix.com/company/sight-sciences-inc/news/sight-sciences-present-upcoming-morgan-200500127</guid>
<pubDate>Tue, 26 Aug 2025 20:05:00 GMT</pubDate>
<description>MENLO PARK, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference in New York, NY. Sight Sciences’ management is scheduled to present on Wednesday, September 10, 2025, at 10:50 am</description>
</item>
<item>
<title>Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance</title>
<link>https://6ix.com/company/sight-sciences-inc/news/sight-sciences-reports-second-quarter-200500537</link>
<guid isPermaLink="true">https://6ix.com/company/sight-sciences-inc/news/sight-sciences-reports-second-quarter-200500537</guid>
<pubDate>Thu, 07 Aug 2025 20:05:00 GMT</pubDate>
<description>MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the second quarter ended June 30, 2025, and raised its revenue guidance while reaffirming its adjusted operating expense guidance, both for full year 2025. Recent Financial</description>
</item>
<item>
<title>Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease</title>
<link>https://6ix.com/company/sight-sciences-inc/news/sight-sciences-announces-results-cost-110000990</link>
<guid isPermaLink="true">https://6ix.com/company/sight-sciences-inc/news/sight-sciences-announces-results-cost-110000990</guid>
<pubDate>Wed, 30 Jul 2025 11:00:00 GMT</pubDate>
<description>Cost-Utility Analysis published in the Expert Review of Pharmacoeconomics and Outcomes ResearchMENLO PARK, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced the results of a cost-utility analysis (CUA) assessing the cost-effectiveness of the TearCare® System compared to cy</description>
</item>
<item>
<title>Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease</title>
<link>https://6ix.com/company/sight-sciences-inc/news/sight-sciences-announces-publication-24-110000568</link>
<guid isPermaLink="true">https://6ix.com/company/sight-sciences-inc/news/sight-sciences-announces-publication-24-110000568</guid>
<pubDate>Tue, 29 Jul 2025 11:00:00 GMT</pubDate>
<description>Mean signs and symptoms for participants in Stage 3 of the SAHARA trial remained statistically significantly better than study baseline at all time points measured up to 24 monthsMENLO PARK, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced that the manuscript detailing 24-</description>
</item>
<item>
<title>Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025</title>
<link>https://6ix.com/company/sight-sciences-inc/news/sight-sciences-report-second-quarter-200500913</link>
<guid isPermaLink="true">https://6ix.com/company/sight-sciences-inc/news/sight-sciences-report-second-quarter-200500913</guid>
<pubDate>Thu, 24 Jul 2025 20:05:00 GMT</pubDate>
<description>MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced it will report financial results for the second quarter ended June 30, 2025, after the market close on Thursday, August 7, 2025. The Company’s management will discuss the results during a conference call beg</description>
</item>
</channel>
</rss>